ArticleInternational journal of emergency medicine2026
Case report: acute phosphine inhalation poisoning in a patient with Down's syndrome.
Article in International journal of emergency medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPhosphine, a highly potent insecticide, can cause damage to multiple physiological systems when inhaled by humans, including the nervous, circulatory, and urinary systems. Currently, there is no effective antidote for phosphine poisoning, which highlights the importance of systematic and effective supportive treatment. CASE PRESENTATION: This paper presents a case of a patient with Down syndrome who had a history of similar gas poisoning and was exposed to high-concentration phosphine gas within 10 min, resulting in inhalation poisoning and shock. Upon admission to our hospital, the patient’s left ventricular ejection fraction (LVEF) dropped to 34% (55%-75%), lactate dehydrogenase (LDH): 586 U/L (120–250 U/L), and creatine kinase-MB (CK-MB): 12.75 ng/ml (0–5 ng/ml), indicating severe cardiac function impairment. Treatment included mechanical ventilation and PICCO-guided hemodynamic management. During treatment, the patient’s whole-blood lactate concentration peaked at 12.5 mmol/L (nearly eight times the normal range), for which continuous renal replacement therapy (CRRT) was administered. Additionally, the comprehensive application of continuous norepinephrine infusion for circulatory maintenance, targeted correction of acidosis, and administration of metaraminol and dobutamine for inotropic support were crucial for improving the patient’s prognosis. Ultimately, the patient was successfully cured.
conclusionsIn this case, disproportionate myocardial injury relative to pulmonary injury was observed, which may be caused by acute exposure to high concentrations of phosphine. Furthermore, the patient’s history of similar gas poisoning and Down syndrome may also contribute to this manifestation. Given the lack of a specific antidote for phosphine poisoning, our supportive treatment emphasizes the importance of PICCO for shock management and early CRRT intervention for lactate elimination and internal environment stabilization. This report provides practical experience for the treatment of phosphine poisoning, particularly for associated cardiac function damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.